"Prostaglandin D2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.
| Descriptor ID |
D015230
|
| MeSH Number(s) |
D10.251.355.255.550.200.200 D23.469.050.175.725.200.200
|
| Concept/Terms |
Prostaglandin D2- Prostaglandin D2
- D2, Prostaglandin
- 11-Dehydroprostaglandin F2 alpha
- 11 Dehydroprostaglandin F2 alpha
- F2 alpha, 11-Dehydroprostaglandin
- alpha, 11-Dehydroprostaglandin F2
- PGD2
- 11-Dehydroprostaglandin F2alpha
- 11 Dehydroprostaglandin F2alpha
- F2alpha, 11-Dehydroprostaglandin
|
Below are MeSH descriptors whose meaning is more general than "Prostaglandin D2".
Below are MeSH descriptors whose meaning is more specific than "Prostaglandin D2".
This graph shows the total number of publications written about "Prostaglandin D2" by people in this website by year, and whether "Prostaglandin D2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2017 | 5 | 0 | 5 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Prostaglandin D2" by people in Profiles.
-
Prostaglandin D2 as a mediator of lymphopenia and a therapeutic target in COVID-19 disease. Med Hypotheses. 2020 Oct; 143:110122.
-
Immuno-pathogenesis of nCOVID-19 and a possible host-directed therapy including anti-inflammatory and anti-viral prostaglandin (PG J2) for effective treatment and reduction in the death toll. Med Hypotheses. 2020 Oct; 143:110080.
-
The relationship between inflammatory markers and spirometric parameters in ACOS, Asthma, and COPD. J Asthma. 2020 12; 57(12):1273-1279.
-
Prostaglandin D2 amplifies lupus disease through basophil accumulation in lymphoid organs. Nat Commun. 2018 02 20; 9(1):725.
-
Authors' Reply to Yilmaz and Türk: "Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives". Drugs. 2017 11; 77(17):1927-1928.
-
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun. 2017 09 19; 8(1):593.
-
Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives. Drugs. 2017 Aug; 77(12):1281-1294.
-
Virus-induced inflammasome activation is suppressed by prostaglandin D2/DP1 signaling. Proc Natl Acad Sci U S A. 2017 07 03; 114(27):E5444-E5453.
-
Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines. J Allergy Clin Immunol. 2017 Oct; 140(4):1090-1100.e11.
-
Preclinical evaluation of an inhibitor of cytosolic phospholipase A2a for the treatment of asthma. J Pharmacol Exp Ther. 2012 Mar; 340(3):656-65.